Intravenous immunoglobulin suppresses IL-10 production by activated B cells in vitro

Jun Tanaka, Kumiko Hirano, Yuzuru Sakamoto, Akiko Sugahara-Tobinai, Shota Endo, Yumi Ito-Matsuoka, Atsushi Nakano, Masanori Inui, Lars Nitschke, Toshiyuki Takai

Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Department of Genetics, University of Erlangen, Erlangen, Germany.
Osaka Research Laboratory, Benesis Corporation, Osaka, Japan.

DOI: 10.4236/oji.2012.24019                

Abstract

A therapeutic preparation of polyclonal human IgG, i.e., intravenous immunoglobulin (IVIg), has been employed to treat several inflammatory and autoimmune disorders. B cells are supposed to be a target of IVIg, but the molecular mechanism is elusive because of the lack of a suitable experimental system. To gain an insight into the beneficial effect of IVIg on B cells, we first established an experimental setting in which IVIg modulates a murine B cell function in vitro, and then aimed at identifying the mechanistic features at the molecular level. Here we show that IVIg down-regulates IL-10 production by CpG-activated B cells in vitro. The responsible component of IVIg was identified as the F(ab’)₂ portion, whose polyclonality is mandatory for the suppressive effect. IVIg, bound to the surface of activated B cells, was found to be co-localized with intracellular SHP-1 on confocal laser microscopy, suggesting that B cell-surface immunoreceptor tyrosine-based inhibitory motif-harboring receptors that recruit SHP-1 are target molecules for IVIg in our experimental setting. Overall, we postulate a scenario in which IVIg attenuates B cells by suppressing IL-10 production, a B cell growth factor, and thus down-regulates the production of pathogenic antibodies.

Keywords

F(ab’)2 Fragment; Immune Inhibition; ITIM Receptors; Polyclonal IgG; SHP-1

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ballow, M. (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. Journal of Allergy and Clinical Immunology, 127, 315-323. doi:10.1016/j.jaci.2010.10.030
[2]	Anthony, R.M., Wermeling, F. and Ravetch, J.V. (2012) Novel roles for the IgG Fc glycan. Annals of the New York Academy of Sciences, 1253, 170-180. doi:10.1111/j.1749-6632.2011.06305.x
[3]	Ibá?ez, C. and Montoro-Ronsano, J.B. (2003) Intravenous immunoglobulin preparations and autoimmune disorders: Mechanisms of action. Current Pharmaceutical Biotechnology, 4, 239-247. doi:10.2174/1389201033489775
[4]	Lemieux, R., Bazin, R. and Néron, S. (2005) Therapuetic intravenous immunoglobulins. Molecular Immunology, 42, 839-848.doi:10.1016/j.molimm.2004.07.046
[5]	Hartung, H.P. (2008) Advances in the understanding of the mechanism of action of IVIg. Journal of Neurology, 255, 3-6. doi:10.1007/s00415-008-3002-0
[6]	Néron, S., Boire, G., Dussault, N., Racine, C., de Brum-Fernandes, A.J., C?té, S. and Jacques, A. (2009) CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro. Archivum Immunologiae et Therapiae Experimentalis, 57, 447-458. doi:10.1007/s00005-009-0048-3
[7]	Branch, D.W., Porter, T.F., Paidas, M.J., Belfort, M.A. and Gonik, B. (2001) Obstetric uses of intravenous immunoglobulin: Successes, failures, and promises. Journal of Allergy and Clinical Immunology, 108, S133-S138. doi:10.1067/mai.2001.117821
[8]	Kaveri, S.V., Dietrich, G., Hurez, V. and Kazatchkine, M.D. (1992) Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clinical and Experimental Immunology, 86, 192-198. doi:10.1111/j.1365-2249.1991.tb05794.x
[9]	Ehrenstein, M.R. and Notley, C.A. (2010) The importance of natural IgM: Scavenger, protector and regulator. Nature Reviews Immunology, 10, 778-786. doi:10.1038/nri2849
[10]	Griffin, D.O. and Rothstein, T.L. (2012) Human b1 cell frequency: Isolation and analysis of human b1 cells. Frontiers in Immunology, 3, 122. doi:10.3389/fimmu.2012.00122
[11]	Nimmerjahn, F. and Ravetch, J.V. (2006) Fc receptors: Old friends and new family members. Immunity, 24, 19-28. doi:10.1016/j.immuni.2005.11.010
[12]	Takai, T., Ono, M., Hikida, M., Ohmori, H. and Ravetch, J.V. (1996) Augmented humoral and anaphylactic responses in Fc RII-deficient mice. Nature, 379, 346-349. doi:10.1038/379346a0
[13]	Jellusova, J. and Nitschke, L. (2011) Regulation of B cell functions by the sialic acid-binding receptors Siglec-G and CD22. Frontiers in Immunology, 2, 96. doi:10.3389/fimmu.2011.00096
[14]	Hayami, K., Fukuta, D., Nishikawa, Y., Yamashita, Y., Inui, M., Ohyama, Y., Hikida, M., Ohmori, H. and Takai, T. (1997) Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. The Journal of Biological Chemistry, 272, 7320-7327. doi:10.1074/jbc.272.11.7320
[15]	Kubagawa, H., Burrows, P.D. and Cooper, M.D. (1997) A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 94, 5261-5266. doi:10.1073/pnas.94.10.5261
[16]	Ujike, A., Takeda, K., Nakamura, A., Ebihara, S., Akiyama, K. and Takai, T. (2002) Impaired dendritic cell maturation and increased TH2 responses in PIR-B-/-mice. Nature Immunology, 3, 542-548. doi:10.1038/ni801
[17]	Nitschke, L., Carsetti, R., Ocker, B., K?hler, G. and Lamers, M.C. (1997) CD22 is a negative regulator of B-cell receptor signalling. Current Biology, 7, 133-143. doi:10.1016/S0960-9822(06)00057-1
[18]	Parr, D., Connell, G., Kells, D. and Hofmann, T. (1976) Fb’2, a new peptic fragment of human immunoglobulin G. Biochemical Journal, 155, 31-36.
[19]	Snigurowicz, J. and Powiertowska, M.R. (1980) Papain hydrolysis products in four M-IgG subclass. Archivum Immunologiae, 28, 265-273.
[20]	Virella, G. and Parkhouse, R. (1971) Papain sensitivity of heavy chain sub-classes in normal human IgG and localization of antigenic determinants for the sub-classes. Immunochemistry, 8, 243-250. doi:10.1016/0019-2791(71)90478-2
[21]	Kubo, T., Uchida, Y., Watanabe, Y., Abe, M., Nakamura, A., Ono, M., Akira, S. and Takai, T. (2009) Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. The Journal of Experimental Medicine, 206, 1971-1982.doi:10.1084/jem.20082392
[22]	Parnes, J.R. and Pan, C. (2000) CD72, a negative regulator of B-cell responsiveness. Immunological Reviews, 176, 75-85.doi:10.1034/j.1600-065X.2000.00608.x
[23]	Li, D.H., Winslow, M.M., Cao, T.M., Chen, A.H., Davis, C.R., Mellins, E.D., Utz, P.J., Crabtree, G.R. and Parnes, J.R. (2008) Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis and Rheumatism, 58, 3192-3204.doi:10.1002/art.23812
[24]	Hoffmann, A., Kerr, S., Jellusova, J., Zhang, J., Weisel, F., Wellmann, U., Winkler, T.H., Kneitz, B., Crocker, P.R. and Nitschke, L. (2007) Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nature Immunology, 8, 695-704. doi:10.1038/ni1480
[25]	Ono, M., Bolland, S., Tempst, P. and Ravetch, J.V. (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc RIIB. Nature, 383, 263-266.doi:10.1038/383263a0
[26]	Leucht, S., Uttenreuther-Fischer, M.M., Gaedicke, G. and Fischer, P. (2001) The B cell superantigen-like interaction of intravenous immunoglobulin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Clinical Immunology, 99, 18-29. doi:10.1006/clim.2001.5004
[27]	Proulx, D.P., Aubin, E., Lemieux, R. and Bazin, R. (2009) Spontaneous internalization of IVIg in activated B cells. Immunology Letters, 124, 18-26. doi:10.1016/j.imlet.2009.03.012
[28]	Sé?té, J.F., Cornec, D., Renaudineau, Y., Youinou, P., Mageed, R.A. and Hillion, S. (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood, 116, 1698-1704. doi:10.1182/blood-2009-12-261461
[29]	Séité, J.F., Guerrier, T., Cornec, D., Jamin, C., Youinou, P. and Hillion, S. (2011) TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. Journal of Autoimmunity, 37, 190-197.doi:10.1016/j.jaut.2011.05.014
[30]	Saraiva, M. and O’Garra, A. (2010) The regulation of IL-10 production by immune cells. Nature Reviews Immunology, 10, 170-181.doi:10.1038/nri2711
[31]	O’Garra, A., Barret, F.J., Castro, A.G., Vicari, A. and Hawrylowicz, C. (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunological Reviews, 223, 114-131.doi:10.1111/j.1600-065X.2008.00635.x
[32]	Kessel, A., Peri, R., Haj, T., Snir, A., Slobodin, G., Sabo, E., Rosner, I., Shoenfeld, Y. and Toubi, E. (2011) IVIg attenuates TLR-9 activation in B cells from SLE patients. Journal of Clinical Immunology, 31, 30-38. doi:10.1007/s10875-010-9469-3